HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 132 | -2 | 91.18M | $6.60B | +5 | −6 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | — | — |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | — | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | — | −1 |
| Q2 2024 | 14 | — | 8.14M | $426.06M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (pasivo) | 3.03M | — | $158.64M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (pasivo) | 3.03M | — | $158.64M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.30M | — | $68.16M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.30M | — | $68.16M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Norges Bank ✦ (pasivo) | 1.22M | — | $63.68M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 478.77K | — | $25.07M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 423.19K | — | $22.16M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 423.19K | — | $22.16M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 377.58K | — | $19.77M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 347.70K | — | $18.21M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 347.70K | — | $18.21M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 347.70K | — | $18.21M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 303.28K | — | $15.88M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Arrowstreet Capital ✦ | 102.75K | — | $5.38M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 48.99K | — | $2.56M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 47.77K | — | $2.50M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 47.77K | — | $2.50M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 47.77K | — | $2.50M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Bridgewater Associates ✦ | 33.22K | — | $1.74M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 28.38K | — | $1.49M | 0.0% | n/c | 1 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 8 tenedores, 32.79M acciones, $43.93M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer, Director · 9.60K acc. · $1.03M
Officer, Director · 3.20K acc. · $344,848
Officer, Director · 7.20K acc. · $765,778
Officer, Director · 5.70K acc. · $587,882
Officer, Director · 9.40K acc. · $985,816
Officer, Director · 4.90K acc. · $509,827
Officer, Director · 900 acc. · $89,062
Officer, Director · 500 acc. · $50,228
Officer, Director · 2.10K acc. · $213,709
Officer, Director · 9.00K acc. · $922,977
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología